Literature DB >> 23457809

Indications for removal of etonogestrel implant within two years of use in Jos, Nigeria.

J T Mutihir1, D D Nyango.   

Abstract

BACKGROUND: Implanon is a new long-term and reversible sub-dermal contraceptive implant in Nigeria. It is a single rod containing 68mg of etonogestrel meant to offer contraception for three years and marketed by Organon.
OBJECTIVE: To determine the indications for removal of Implanon rods from clients within a two-year period.
DESIGN: A retrospective review of 30 consecutive Implanon removals within the study period.
SETTING: The fertility regulation unit of the department of obstetrics and gynaecology of the Jos University Teaching Hospital, North-Central Nigeria.
RESULTS: A total of 30 clients requested for and had their Implanon rods removed out of 669 insertions constituting 95.5% crude continuation rate in the second year. The clients were of mean age 31.4 +/- 6.2 years, mean parity 2.9 +/- 1.8 and mean number of living children 2.7 +/- 1.6. There was an average weight gain of 1.9 kg. The most common indication for removal was menstrual disruption (33.3%). Desire for another pregnancy closely followed (30.0%). Weight gain was another indication for discontinuation (13.3%). Two women were pregnant at insertion of the implant. There was one failure of the method with pregnancy as a result. Spousal disapproval was an indication for removal in two cases.
CONCLUSION: Like all progestin-only contraceptive methods, menstrual disruption was the most common indication for removal of implants. Inadvertent insertion of implants with existing pregnancy is of concern and should be avoided as much as is possible. In doubtful cases at insertion, this insertion should be deferred or serum beta-HCG should be assessed to exclude chemical pregnancy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 23457809

Source DB:  PubMed          Journal:  East Afr Med J        ISSN: 0012-835X


  7 in total

1.  Discontinuation of implants use and associated factors among women attending health facility clinics in Hawassa City, Southern Ethiopia, 2019; cross sectional study.

Authors:  Belay Amare Abebe; Mulu Reda Terefe
Journal:  Contracept Reprod Med       Date:  2020-10-23

2.  Discontinuation of Reversible Long-Acting Contraceptive and Associated Factors among Female Users in Health Facilities of Hawassa City, Southern Ethiopia: Cross-Sectional Study.

Authors:  Belay Amare Abebe; Nega Assefa; Bezatu Mengistie
Journal:  Open Access J Contracept       Date:  2020-08-26

3.  Early Implanon Discontinuation and Associated Factors among Implanon User Women in Debre Tabor Town, Public Health Facilities, Northwest Ethiopia, 2016.

Authors:  Mengstu Melkamu Asaye; Tewodros Syoum Nigussie; Worku Mequannt Ambaw
Journal:  Int J Reprod Med       Date:  2018-01-21

Review 4.  There might be blood: a scoping review on women's responses to contraceptive-induced menstrual bleeding changes.

Authors:  Chelsea B Polis; Rubina Hussain; Amanda Berry
Journal:  Reprod Health       Date:  2018-06-26       Impact factor: 3.223

5.  Determinants of early discontinuation of etonogestrel sub-dermal implant among reproductive-age women in Legambo district, Northeast Ethiopia: An unmatched case-control study.

Authors:  Yesuf Yimer; Niguss Cherie; Yitaysh Damtie
Journal:  SAGE Open Med       Date:  2022-03-29

6.  The prevalence of Implanon discontinuation and associated factors among Ethiopian women: A systematic review and meta-analysis.

Authors:  Aklilu Habte; Aiggan Tamene; Demelash Woldeyohannes; Biruk Bogale; Dejene Ermias; Fitsum Endale; Addisalem Gizachew; Merertu Wondimu; Dawit Sulamo
Journal:  Womens Health (Lond)       Date:  2022 Jan-Dec

7.  A qualitative study on reasons for early removal of Implanon among users in Arba Minch town, Gamo Goffa zone, South Ethiopia: a phenomenological approach.

Authors:  Mesfin Mamo Utaile; Mesfin Kote Debere; Etsehiwot Tilahun Nida; Dube Jara Boneya; Amsale Tekle Ergano
Journal:  BMC Womens Health       Date:  2020-01-02       Impact factor: 2.809

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.